MedPath
NMPA Approval

Recombinant Human Papillomavirus 9-Valent (Types 6,11,16,18,31,33,45,52,58) Vaccine (Escherichia coli)

国药准字S20250023

May 27, 2025

Drug Information

九价人乳头瘤病毒疫苗(大肠埃希菌)

馨可宁9(Cecolin 9)

注射剂

每支0.5 mL,每1次人用剂量为0.5 mL(含重组HPV 6型L1蛋白30 μg,重组HPV 11型L1蛋白40 μg,重组HPV 16型L1蛋白60 μg,重组HPV 18型L1蛋白40 μg,重组HPV 31型L1蛋白20 μg,重组HPV 33型L1蛋白20 μg,重组HPV 45型L1蛋白20 μg,重组HPV 52型L1蛋白20 μg和重组HPV 58型L1蛋白20 μg)

生物制品

May 27, 2025

Company Information

Applicant Company

福建省厦门市海沧区山边洪东路50号一层

Manufacturing Company

福建省厦门市海沧区山边洪东路52号、60号

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.

九价人乳头瘤病毒疫苗(大肠埃希菌) - NMPA 批准文号 | MedPath